Dutasteride-<sup>13</sup>C<sub>6</sub>

Dutasteride-13C6

CAT N°: 25313
Price:

From 548.00 465.80

Dutasteride-13C6 is intended for use as an internal standard for the quantification of dutasteride (Item No. 15956) by GC- or LC-MS. Dutasteride is a dual inhibitor of 5?-reductase types I and II (Kis = 6 and 7 nM, respectively).{25831,25832,43107} Its inhibition is time-dependent with apparent Ki values of 17 and 4.3 nM at 10- and 30-minute reaction times, respectively.{25831} Dutasteride decreases prostate weight in a rat model of benign prostatic hypertrophy induced by testosterone after castration when administered daily for 28 days at doses of 0.045 mg/kg as a solution or 0.756 mg/kg in subcutaneous microspheres.{43105} It also decreases prostate weight in large probasin-large T antigen mice, a transgenic model of prostate cancer.{43106} Formulations containing dutasteride have been used in the treatment of benign prostatic hyperplasia.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-bis(trifluoromethyl)phenyl-1,2,3,4,5,6-13C6)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
  • Correlated keywords
    • 1217685-27-2 GCMS LCMS 13C C6
  • Product Overview:
    Dutasteride-13C6 is intended for use as an internal standard for the quantification of dutasteride (Item No. 15956) by GC- or LC-MS. Dutasteride is a dual inhibitor of 5?-reductase types I and II (Kis = 6 and 7 nM, respectively).{25831,25832,43107} Its inhibition is time-dependent with apparent Ki values of 17 and 4.3 nM at 10- and 30-minute reaction times, respectively.{25831} Dutasteride decreases prostate weight in a rat model of benign prostatic hypertrophy induced by testosterone after castration when administered daily for 28 days at doses of 0.045 mg/kg as a solution or 0.756 mg/kg in subcutaneous microspheres.{43105} It also decreases prostate weight in large probasin-large T antigen mice, a transgenic model of prostate cancer.{43106} Formulations containing dutasteride have been used in the treatment of benign prostatic hyperplasia.

We also advise you